Skip to search formSkip to main contentSkip to account menu

GSK 461364A

Known as: GSK-461364A, GSK461364A 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Thiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months… 
2013
2013
The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
BACKGROUND Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are the most aggressive forms of… 
2009
2009
Kinase Inhibitor 4 Minisymposium summary
In recent years no cancer therapeutic class has undergone more prolific or successful drug development efforts than the kinase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)